Dystrophin Market

Market Synopsis:

Global Dystrophin Market is valued at USD 1.46 Billion in 2022 and is projected to attain a value of USD 29.53 Billion by 2030 at a CAGR of 45.60% during the forecast period, 2022–2028. Factors such as the high prevalence of DMD in the region, favourable funding conditions for DMD research and development, high healthcare expenditure potential among the population in developed countries, and the availability of medical reimbursement in various regions around the world are propelling the Dystrophin Market forward.

COVID-19's increased prevalence is expected to have an impact on market growth over the projection period. The COVID-19 dilemma has had a significant and immediate impact on the healthcare industry. Because of the unexpected impact on the supply chain and the limits imposed on manufacturing and supply operations during the early stages of the coronavirus pandemic, most companies suffered a minor loss in the first few quarters. COVID-19, on the other hand, has raised demand for therapeutics and drugs, especially Dystrophin, and some important players have seen favourable sales growth as a result of the increased demand.

Emergence of Mutation-Specific Therapies, Rising Incidence of the Condition, and Improved Diagnostics

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Throughout the forecast period, the market is expected to grow at a rapid pace. The advent of mutation-specific medicines, increased incidence of the disease, and enhanced diagnostics are all contributing to the growth. The market is likely to develop as a result of government initiatives encouraging target-specific treatments and attractive reimbursement rules. Furthermore, the treatment area is expected to expand as other targeted medicines, such as Exondys51, Translarna, and Emflaza, gain recognition.

High Cost of Therapeutics

The high cost of therapies continues to be a barrier to the expansion of the Dystrophin, medication landscape. Governments in all major regions, however, are adopting inexpensive healthcare policies, which has an impact on company pricing strategies as well as reimbursement scenarios. Premium price potential for emerging Dystrophin, treatments is likely to be hampered by rising cost consciousness. The lack of established processes for determining the clinical efficacy of medications, as well as stringent regulatory approvals, remain key obstacles to overcome. Increasing treatment choices for underserved groups including babies and no ambulant patients, on the other hand, is expected to bode well for the industry in the near future.

Market Segmentation:

The Global Dystrophin Market can be segmented by Product Type into Exondys51, Translarna, Emflaza and Others. Based on Approach, global Dystrophin Market can be segmented into Exon Skipping, Anti-Inflammatory Therapy, Stop Codon Read-Through, Others Approaches. Based on Region, the Dystrophin Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Exon skipping accounted for 45.7% of the overall business in 2021 and is expected to increase rapidly in the coming years as regulatory authorisation in Europe and other areas of the world is granted. However, in undeveloped countries, insufficient awareness of treatments is projected to stifle growth over the projection period. Because of the industry's and healthcare professionals' favourable attitudes toward the development of new therapies, emerging techniques for muscular dystrophy therapeutics are predicted to grow at a CAGR of 80.1% from 2016 to 2028.

North America to Continue Dominating the Dystrophin Market

Owing to product launches in the United States, North America is likely to have a high demand, followed by Europe. High incidence of muscular Dystrophin in the region, accelerated FDA approval of drug in the region, favourable funding scenario for R&D in the field of Dystrophin, high healthcare expenditure potential among the North American population, and availability of medical reimbursement in the region are among the key factors supporting the Dystrophin market's growth in North America.

Key Players:

Key participants include PTC Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical Inc, Wave Life Sciences, Bristol-Myers Squibb and Catabasis Pharmaceuticals among others.

Dystrophin Market is segmented as follows:

Dystrophin Market is tabulated as follows: